BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BioFocus DPI and Argenta Discovery Inc. Announce Drug Discovery Collaboration With AstraZeneca PLC (AZN) in Respiratory and Inflammatory Disease


3/14/2012 6:48:27 AM

SAFFRON WALDEN & HARLOW, England & MÖLNDAL, Sweden--(BUSINESS WIRE)-- Galapagos’ service companies, BioFocus and Argenta, today announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases.

Under the terms of the collaboration, each AstraZeneca project will engage the medicinal chemistry, biology and ADME/PK capabilities of either BioFocus or Argenta, and will also be able to access the full suite of in vivo respiratory pharmacology models which reside within Argenta.

Financial details were not disclosed.

“Both BioFocus and Argenta have worked extensively with AstraZeneca over the past 10 years, and this new collaborative agreement brings enormous capability and experience to each AstraZeneca project we work on. We are delighted to renew our new drug discovery alliance with one of the world’s leading research-based pharmaceutical companies,” added Dr. Chris Newton, SVP Galapagos Services.

“We continue to be impressed by the strength of the BioFocus and Argenta technology platforms and the evident depth of experience of the scientists that will be engaged on our projects addressing respiratory and inflammatory conditions”, said Dr. John Steele, VP R&I Innovative Medicines Science Unit at AstraZeneca.

About BioFocus

BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capability in neurodegenerative diseases, inflammatory diseases and with a growing track record of delivering candidates against rare and neglected diseases.

BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client projects to deliver targets, hits, leads and candidate pre-clinical drugs. The company employs 210 exceptionally qualified and industry experienced scientists at its three research centers in the UK, Switzerland and the Netherlands.

Since its foundation in 1997, BioFocus has striven to produce high quality data for its clients and this quality is assured by ISO9001 qualification validated by regular, independent inspection of all BioFocus research centers.

For more information visit www.biofocus.com

About Argenta

Argenta’s contract research, which includes expertise in medicinal chemistry, computer-aided drug discovery, in vitro biology, analytics, in vivo pharmacokinetics, pharmacology and world-leading respiratory models, has a strong reputation for scientific excellence. Argenta was acquired by Galapagos in February 2010 and employs over 160 people in the UK with its main operations in Harlow. More info at: www.argentadiscovery.com

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50203502&lang=en

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50203502&lang=en

Contact:

Galapagos Services (BioFocus and Argenta)

Chris Newton

SVP Galapagos Services

E-mail: chris.newton@glpg.com

Tel: +44 (0)1799 533 500

or

Zyme Communications

Katie Odgaard

E-mail : katie.odgaard@zymecommunications.com

Tel : +44 (0)7787 502 947




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->